An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
Ptacin, Jerod L., Caffaro, Carolina E., Ma, Lina, San Jose Gall, Kristine M., Aerni, Hans R., Acuff, Nicole V., Herman, Rob W., Pavlova, Yelena, Pena, Michael J., Chen, David B., Koriazova, Lilia K., Shawver, Laura K., Joseph, Ingrid B., Milla, Marcos E.
Published in Nature communications (09.08.2021)
Published in Nature communications (09.08.2021)
Get full text
Journal Article
A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism
Ptacin, Jerod L, Ma, Lina, Caffaro, Carolina E, Acuff, Nicole V, Germar, Kristine, Severy, Peter, Qu, Yanyan, Vela, Jose-Luis, Cai, Xinming, San Jose, Kristine M, Aerni, Hans R, Chen, David B, Esche, Ean, Ismaili, Taylor K, Herman, Rob, Pavlova, Yelena, Pena, Michael J, Nguyen, Jasmine, Koriazova, Lilia K, Shawver, Laura K, Joseph, Ingrid B, Mooney, Jill, Peakman, Mark, Milla, Marcos E
Published in Communications medicine (26.03.2024)
Published in Communications medicine (26.03.2024)
Get full text
Journal Article
Abstract 3258: THOR-707, a novel not-alpha IL-2, elicits durable pharmacodynamic responses in non-human primates and efficacy as single agent and in combination with anti PD-1 in multiple syngeneic mouse models
Joseph, Ingrid B., Ma, Lina, Ptacin, Jerod L., Caffaro, Carolina E., Aerni, Hans R., Jose, Kristine M. San, Pena, Michael J., Herman, Robert W., Pavlova, Yelena, Chen, David B., Bragstad, Ken, Li, Shukuan, Nguyen, Jasmine, Shawver, Laura K., Koriazova, Lilia K., Milla, Marcos E.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article